Literature DB >> 59582

Creatine phosphokinase levels in children with severe developmental disturbances.

D J Cohen, W Johnson, B K Caparulo, J G Young.   

Abstract

Serum creatine phosphokinase (CPK) levels were studied in individuals: 40 psychotic children suffering from childhood autism, atypical personality development, and childhood schizophrenia; five children with childhood aphasia; 22 children with severe personality disorders; 29 normal children and normal siblings of psychotic children; and 14 normal parents of psychotic children. Creatine phosphokinase levels from the entire population of adults and children were normally disturbed, and the mean CPK levels for the eight diagnostic groups were within normal limits. Those 22 children with personality disorders had significantly higher CPK levels than the other diagnostic groups. This relatively higher level of CPK may be related to vulnerability to later development of schizophrenic spectrum disorders. There was no apparent relationship between CPK levels and motor activity, nor was there any change in the level of CPK during a trial of psychoactive medication. Creatine phosphokinase levels remained relatively stable on test-retest determination.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 59582     DOI: 10.1001/archpsyc.1976.01770060025004

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  3 in total

Review 1.  Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis.

Authors:  D A Rossignol; R E Frye
Journal:  Mol Psychiatry       Date:  2011-01-25       Impact factor: 15.992

Review 2.  Metabolic Dysfunction Underlying Autism Spectrum Disorder and Potential Treatment Approaches.

Authors:  Ning Cheng; Jong M Rho; Susan A Masino
Journal:  Front Mol Neurosci       Date:  2017-02-21       Impact factor: 5.639

3.  Case report: One child with an autism spectrum disorder who had chronically elevated serum levels of CK and CK-MB.

Authors:  Ping Rong; Shuyi Zhao; Qianfang Fu; Mengrui Chen; Libin Yang; Yifei Song; Xilian Zhang; Rong Ma
Journal:  Front Psychiatry       Date:  2022-09-06       Impact factor: 5.435

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.